De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
Table 1
Clinical data and blood and urine test results of the two patients.
Patient 1
Patient 2
Reference value
Age
54 years
78 years
Sex
Female
Female
Height
169 cm
160 cm
Weight
70.9 kg
62 kg
After 2. vac.
Before 1. vac.
After 2. vac.
BVAS
17
0
12
0–63 Points
Blood tests
Leukocytes
10.6 G/L
6.7 G/L
6.4 G/L
3.7–10.0 G/L
Hemoglobin
9.2 g/dL
13.2 g/dL
9.3 g/dL
12.0–16.0 g/dL
CRP
11.79 mg/dL
0.10 mg/dL
0.43 mg/dL
<0.50 mg/dL
Urea
9.3 mmol/L
12.0 mmol/l
34.8 mmol/L
2.8–7.2 mmol/L
Creatinine
187 μmol/L
142 μmol/L
728 μmol/L
44–80 μmol/L
MPO-ANCA (Phadia)
106 IU/mL
99 IU/L
>134 IU/mL
<5 IU/mL
SARS-CoV-2 S antibody titer
>2572 BAU/mL
81.45 BAU/mL
<0.82 BAU/mL
Urine tests
Hematuria
++++
++
+++
1-++++
Protein/creatinine ratio
0.44 g/g
0.15 g/g
3.56 g/g
<0.11 g/g
vac, vaccination; BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; BAU/ml, binding antibody units/ml. The ELECSYS Anti-SARS-CoV-2 S (Spike/RBD-Protein) test from Roche Company was used to measure SARS-CoV-2 antibodies.
